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Objectives. To assess the outcome of cold-stored venous allografts in critically ischemic limbs in patients with no ipsilat-
eral autogenous greater saphenous vein.
Design. A non-randomised, retrospective, single-center study.
Methods. From September 2000 to June 2006, 46 cold-stored venous allografts obtained during multiorgan harvest were
implanted into 44 critically ischaemic limbs of 43 patients. The indication for reconstructions was rest pain (24%) or tissue
lost (76%). Sixty-seven percent of procedures were performed as secondary reconstructions, and 61% of veins were anas-
tomosed to tibial or pedal arteries. Thirty-seven percent of patients received prednisone, and 46% tacrolimus as postoper-
ative immunosuppressive therapy. Mean patient follow-up period was 13.3 months (range 1 week to 60 months).
Results. The secondary patency rate for the cohort was 83 5.6% at 1 month, 64 8.2% at 6 months, 57 10.0% at 12
months and 46 10.7% at 24 months. Limb salvage rate was 96 3.1% at 1 month, 78 6.9% at 6 months, 71 8.1% at
12 months and 50 11.8% at 24 months.
Conclusion. Cold-stored venous allografts are an alternative conduit for limb salvage procedures when ipsilateral autog-
enous vein is unavailable.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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A good-quality autologous vein provides the best
results for infra-inguinal bypass.1 In a considerable
group of patients with critical ischaemia, the greater
saphenous vein is not available for vascular recon-
struction.2e4 The use of a prosthetic graft in the field
of chronic leg ulcerations is accompanied with
a high risk of infection.5
In such circumstances, alternative autogenous con-
duits such as an arm vein,6 lesser saphenous vein7 or
composite autogenous vein8 are used. In addition, al-
logenous materials such as cryopreserved venous allo-
grafts,9 cold-stored venous allografts,10 cryopreserved
arterial allografts,11 cold-stored arterial allografts,12
umbilical cord vein allografts13 or Ovine collagen biog-
rafts14 are available to use as conduits.
However, arterial as well as venous allografts are
antigenic and the process of chronic rejection is a lim-
iting factor in long-term patency rates of these by-pass
conduits.
*Corresponding author. I. Matia, Department of Transplant Surgery,
Institute for Clinical and Experimental Medicine, Videnska 1958/9,
140 21 Prague, Czech Republic.
E-mail addresses: ivmi@medicon.cz, ivanmatia@gmail.com1078–5884/000424+ 08 $32.00/0  2007 European Society for VascuAt our Institute, the Vascular Surgery Unit is inte-
grated closely with the Transplant Center, so it is pos-
sible to obtain allogenic blood vessels for vascular
reconstruction during regular multi-organ harvests.15
Over the past six years we have used cold-stored ve-
nous allografts in patients with no suitable ipsilateral
greater saphenous veins and critically ischemic limbs.
This present paper reports our results.
Material and Methods
The work was approved by the Ethical Committee of
the Institute for Clinical and Experimental Medicine
in Prague. The work is a retrospective study dealing
with the critically ischaemic lower limbs treated by
cold-stored venous allograft reconstructions. Ipsilat-
eral autogenous greater saphenous vein was unavail-
able in all patients.
Patient population
From September 2000 to June 2006, 46 cold-stored
venous allografts were implanted into 44 critically
ischaemic limbs of 43 patients (men 21, women 22).
Mean patient age at primary graft implantation waslar Surgery. Published by Elsevier Ltd. All rights reserved.
425Venous Allografts in Critically Ischaemic Limbs66.8 years (range 46 to 85 years). Demographic data
for all 43 patients are shown in Table 1.
The indication for the 46 reconstructions was either
rest pain (n¼ 11, 24%) or tissue lost (n¼ 35, 76%).
Suitable ipsilateral autogenous greater saphenous
vein was not available in these patients. The most
frequent reason for lack of ipsilateral vein was it’s
use as conduit for a prior leg bypass (43%) (Table 2).
Sixty-seven percent of 46 cold-stored venous allograft
reconstructions were secondary or even tertiary
procedures, performed after a previous failed infrain-
guinal reconstruction. In 59 percent of venous
allograft reconstructions, there was no contralateral
autogenous greater saphenous vein available, mainly
because of it’s previous harvest (20%) (Table 2). In
the remaining 41 percent of patients with a suitable
contralateral vein we elected not to utilise this because
of the high risk that it would be required for future
intervention in that leg.16
All patients underwent preoperative arteriography.
The quality of the peripheral outflow tract distal to the
graft was outlined by using Rutherford’s run-
off-index.17 The mean value of the index for the 46
reconstructions was 4.9 (range 2 to 8, SD 1.8).
Harvest and preservation of venous grafts
All venous allografts (greater saphenous veins) were
obtained from donors with the diagnosis of brain
death in the course of a multiorgan harvest. The
mean age of the donors was 32 years (range 17 to 54
years).
After removal, the venous grafts were flushed with
heparinised conservation solutions commonly used in
multiorgan harvests, i.e. Custodiol or University of
Wisconsin. The grafts were stored at a temperature
of about 4 degrees Centigrade using the same types
of solutions as those used for flushing, with no addi-
tional antibiotics. The mean cold ischemic time of ve-
nous grafts was 5 days (range 5 hours to 13 days). The
patients indicated for the use of venous allograft were
integrated into a waiting list similar to that used for
potential recipients in solid organ transplantation.
The ABO compatibility, but no HLA compatibility,
was maintained between donors and recipients of
venous allografts. Similarly, no cross-match was
Table 1. Demographic data for 43 patients in whom cold-stored
venous allografts were used
Characteristic N %
Diabetes 30 70
Tobacco use 20 47
Ischaemic heart disease 26 61performed. In all organ donors bacteriological and
serological tests (for HIV, hepatitis C, hepatitis B,
cytomegalovirus, syphilis, Epstein-Barr virus) were
performed before the multiorgan harvest.
Characteristics of procedures
Characteristics of the operative procedures of the 46
venous allograft are shown in Table 3.
Immunosupressive and antithrombotic therapy
From September 2000 to September 2004 a variety of
immunosuppresive protocols including prednisone,
azathioprime, cyclosporine A were used in patients
after the allovenous reconstructions (Table 4). Drug
dosages and the duration of administration were not
standardized. In September 2004, we started using
an immunosuppressive protocol consisting of orally
administered FK 506 (tacrolimus, Prograf, Astellas
Pharma Ltd.), with the drug blood level generally
Table 2. Reasons of lack of suitable ipsilateral and contralateral
autogenous saphenous veins in 46 reconstructions
Greater saphenous vein Ipsilateral leg Contralateral leg
Previously used for
vascular reconstruction
20/46 43% 9/46 20%
Previously used for
coronary reconstruction
7/46 15% 5/46 11%
Previously stripped 3/46 7% 4/46 10%
Poor quality determined
by ultrasound vein mapping
5/46 11% 3/46 7%
Poor qualty determined
during op revision
11/46 24% 1/46 2%
History of leg amputation e 5/46 11%
Expected need for the
vein in the future*
e 19/46 41%
* All patients with diabetes mellitusþ coronary artery diseaseþ
age under 70 as published by Tarry et al.16
Table 3. The sites of proximal and distal anastomosis of 46 venous
allografts reconstructions
No %
Inflow artery External iliac 2 4
Common femoral 33 72
Superficial femoral 4 9
Popliteal, above knee 1 2
Prosthesis, aortofemoral 2 4
Prosthesis, ilicofemoral 3 7
Prosthesis, femoropopliteal 1 2
Outflow artery Popliteal, above knee 9 20
Popliteal, below knee 9 20
Tibial anterior 7 15
Tibial posterior 11 23
Peroneal 7 15
Pedal 3 7Eur J Vasc Endovasc Surg Vol 34, October 2007
426 I. Matia et al.ranging between 4 and 7 ng/ml. Tacrolimus was ad-
ministered throughout the entire period of allograft
patency and blood levels were determined periodi-
cally. This type of immunosuppression was used in
21 (46%) patients (Table 4).
Anticoagulants and antithrombotic drugs
The drugs used postoperatively to influence blood co-
agulation as of the date of discharge are summarised
in Table 5.
Follow up periods
We defined three follow up periods, namely for the
patient, for the limb, and for the vascular procedure.
Each of them started on the day of the operation.
The death of the patient or the date when the patient
was last known to be alive were the end points of the
patient follow-up period. The follow-up period for the
patency rate ended when the graft was confirmed to
be occluded or last known to be patent. The graft
patency was evaluated only by a vascular surgeon
or diagnostic tests. The follow-up period for the
limb salvage rate ended when a major limb amputa-
tion was done, the patient died, or the patient was
last known to have an affected limb. A major limb
amputation was defined as an amputation which
was unable to preserve a sufficiently functional foot
remnant to allow standing and walking without
a prosthesis.17
Table 4. Type of immunosuppression in 46 venous allografts
reconstructions
Immunosuppressive protocol N %
No immunosuppression 5 11
Prednisone 17 37
Azathioprime 1 2
Cyclosporine A 2 4
Tacrolimus 21 46
Table 5. Antithrombotic drugs in 41 venous allografts reconstruc-
tions patent as of the date of dimission
N %
acetylsalicylic acid 15 37
ticlopidine 17 42
LMWH 3 7
warfarin 2 5
warfarinþ acetylsalicylic acid 2 5
warfarinþ ticlopidine 1 2
Clopidogrelþ acetylsalicylic acid 1 2
LMWH, low molecular weight of heparin.
Eur J Vasc Endovasc Surg Vol 34, October 2007From September 2004 we employed along with the
standard immunosuppressive protocol a standard
protocol for duplex ultrasound surveillance of patients
after the allovenous reconstructions. The patients were
seen in three-monthly intervals to check the graft
patency and the FK 506 blood levels as well. The
patency of reconstructions was verified by clinical
examinations as well as ultrasonography at identical
time intervals. If signs of bypass stenosis were ob-
served with duplex ultrasonography, angiography
(conventional or computed) was performed.
Statistical analysis
Patient survival rates, graft patency rates, and limb
salvage rates were determined by the KaplaneMeier
method. Differences between groups were tested for
significance using Wilcoxon’s signed rank test. Differ-
ences between groups were considered significant for
P values less than 0.05.
Results
The mean patient follow-up period was 13.3 months
(range 1 week to 60 months), the mean limb salvage
follow-up period was 13.4 months (range 1 day to
58 months) and the mean graft patency rate follow-
up period was 10 months (range 1 day to 56.5
months), respectively.
There were no deaths during the thirty-day perio-
perative period. The overall thirty-day morbidity was
24%. Systemic complications included acute GIT
hemorrhage in 1 patient (2%). Local complications
included wound infection (11%), wound hemorrhage
without surgical intervention (4%), wound hemor-
rhage that necessitated surgical intervention (2%),
vein allograft bypass rupture (2%), and graft
thrombosis with limb amputation (2%). Patients
survival rate was 100% at 1 month, 92 4.6% at
3 months, 88 5.7% at 6 months, 88 5.7% at 12
months, 88 5.7% at 24 months and 74 15.4% at
36 months (Fig. 1).
The primary patency rate for the cohort was
83 5.6% at 1 month, 70 7.1% at 3 months, 47 8.3%
at 6 months, 35 9.4% at 12 months, 31 9.0% at
24 months and 15 8.1% at 36 months (Fig. 2).
Six endovascular procedures (5 PTA, 1 PTA/stent)
were needed to maintain the primary patency of ve-
nous allografts. The primary assisted patency rate
for the cohort was 83 5.6% at 1 month, 73 6.9%
at 3 months, 61 8.3% at 6 months, 57 10.0% at 12
months, 46 10.7% at 24 months and 23 10.1% at
36 months.
427Venous Allografts in Critically Ischaemic LimbsFig. 1. Patients survival curve. KaplaneMaier method. Number at rist (% SEM).Six surgical thrombectomies and two local usages
of tissue plasminogen activator were needed to main-
tain the secondary patency of venous allografts. The
secondary patency rate for the cohort was 83 5.6%
at 1 month, 73 6.9% at 3 months, 64 8.2% at 6
months, 57% 10.0% at 12 months, 46 10.7% at 24
months and 31 11.4% at 36 months (Fig. 3).
Limb salvage rate was 96 3.1% at 1 month,
81 6.3% at 3 months, 78 6.9% at 6 months,
71 8.1% at 12 months, 50 11.8% at 24 months and
43 12.2% at 36 months (Fig. 4).To compare the influence of FK 506 immunosup-
pression, the cohort of patients was divided into
a group with standard FK 506 immunosupression
(N¼ 21) and one with other types or no immunosup-
pression (N¼ 25). The primary patency rate for the FK
506 group was 76 9.3% at 1 month, 65 10.8% at
3 months, 59 11.5% at 6 months and 16 14.0% at
12 months. The primary patency rate for the group
of patients with other type or no immunosuppresion
was 88 6.5% at 1 month, 75 8.9% at 3 months,
42 10.5% at 6 months and 42 10.5% at 12 months,Fig. 2. Primary patency curve for 46 revascularizations procedures with cold-stored venous allografts. KaplaneMaier
method. Number at rist (% SEM).Eur J Vasc Endovasc Surg Vol 34, October 2007
428 I. Matia et al.Fig. 3. Secondary patency curve for 46 revascularizations procedures with cold-stored venous allografts. Kaplane
Maier method. Number at rist (% SEM).respectively. The secondary patency rate for the FK
506 immunosuppressed group was 76 9.3% at 1
month, 65 10.8% at 3 months, 65 10.8% at 6
months and 44 19.1% at 12 months, and for the
other group 88 6.5% at 1 month, 79 8.3% at 3
months, 65 9.9% at 6 months and 60 10.5% at 12
months, respectively.
No statistical differences in patient survival, limb
salvage rate, primary and secondary patency rateswere observed between the groups using Wilcoxon’s
signed rank test.
Discussion
In this study, the greater saphenous veins obtained
from brain-dead donors in the course of a multi-organ
harvest were used in 43 patients with critical lower
limb ischaemia. All vascular reconstructions wereFig. 4. Limb salvage curve for 44 critically ischaemic limbs treated by cold-stored venous allografts reconstructions.
KaplaneMaier method. Number at rist (% SEM).
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429Venous Allografts in Critically Ischaemic Limbsperformed as limb-salvage procedures. The ipsilateral
autogenous greater saphenous vein was not available
in any of presented patients, and almost 70% of them
had diabetes mellitus.
Venous allografts are used in patients with no suit-
able autogenous vein when polytetrafluoroethylene
(PTFE) grafts are not recommended. This concerns
mainly patients with gangrene or poor run-off.1 There
are various types of venous allografts that can be
used, which differ in how they are preserved. The
most frequently used ones are glutaraldehyde venous
allografts, followed by cryopreserved and cold-stored
venous allografts.18,19 However, a direct comparison
between various allografts or preservation techniques
is not possible because of the heterogeneity of indi-
vidual studies and the absence of a study directly com-
paring various types of allografts.18 AMeta-Analysis19
suggests that there are probably no statistically sig-
nificant differences between the various types of
allografts.
Currently, only four studies describing the use of
venous allografts preserved at 4 for infrainguinal
bypasses have been published: Van Reedt Dortland
et al.,20 de Leersnijder et al.,21 Rebane et al.22 and
Streinchenberger et al.10 (Table 6) Nevertheless, all of
these studies were undertaken on venous allografts
that were harvested during varicose vein surgery.
The grafts were stored in a saline solution containing
antibiotics. Because of the difficult assembly of ve-
nous allografts, most of them were used as a part of
composite grafts made with either polytetrafluoro-
ethylene or polyurethane prostheses,10 or were com-
posed of more than two vein segments to obtain
a conduit of a convenient length.21,22 The cold ischae-
mic time ranged from 10 days22 to six months21 and
no immunosuppressive drugs were used in postoper-
ative protocols (Table 6). Diabetes was the only factor
independently associated with a worse outcome in
one study of cryopreserved venous allografts.23
Our cohort of patients differs from that in the
previously mentioned studies of venous allograft
reconstructions. Most of our patients suffered from
diabetes (70%) and ischaemic heart disease (61%), all
of them have had critical ischaemia of the legs, 67%
of allovenous bypasses were performed as the second-
ary procedure and the site of distal anastomosis were
crural or pedal arteries in 61% of the total reconstruc-
tions. Nevertheless, the 1-year limb salvage (71%) and
secondary patency rates (57%) presented in this study
are comparable to that of cryopreserved (78%, 48%) or
cold-stored venous allografts (76%, 64%) presented in
the Meta-Analysis by Albers et al.19
Recent immunological studies have shown that ve-
nous allografts, cold-stored as well as cryopreserved, Ta
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430 I. Matia et al.are antigenic24 and that the antigenicity is not modi-
fied by cryopreservation.25e27 Immunosuppression
has been examined as a possible adjunct to decrease
the antigenicity of the venous allograft, mainly in an-
imal models.28e30 The immunosuppressive therapy
after allovenous reconstructions is generally not
used. Posner et al.31 evaluated a combination of
low-dose cyclosporine, azathioprime, prednisone,
warfarin, aspirin and vasodilators on the patency of
cryopreserved vein bypasses in humans and found
a significantly improved patency (59% vs. 17%) at 1
year. Carpenter and Tomaszewski,32 however, were
unable to show any benefit to low-dose immuno-
suppression with azathioprime when compared to
controls in regard to graft patency or limb salvage.
The drug used most frequently as an immunosup-
pressant in the beginning of our study was predni-
sone. From September 2004 we started to use an
immunosuppressive protocol composed of oral FK
506 (tacrolimus, Prograf, Astellas Pharma Ltd.)
with drug blood level between 4 to 7 ng/ml. FK
506 is a modern immunosuppressant used widely
after solid organ transplantations. Tacrolimus- when
compared to cyclosporine-based immunosuppressive
therapy in kidney transplantations, resulted in a
significantly reduced risk of graft failure, without
an increase in the incidence of adverse events.33,34
Moreover, the inhibition of the transforming growth
factor e beta (TGF-beta) production by FK 506 could
make the drug eligible for use in vascular sur-
gery.35,36 TGF-beta is an important cytokine involved
in the process of fibrosis. Increased expression of
TGF-beta mRNA is associated with saphenous vein
bypass graft disease and with postangioplasty
stenosis.37
FK 506 was administered as a monotherapy in low
dosages to our patients and no adverse effects have so
far been observed. In comparison to other studies, no
aneurysmal dilatation occurred in any of the patients
(Table 6). This may have resulted from immuno-
suppression of the immune system, the short dura-
tion of the cold-stored preservation period, as well
as the properties of preservation solution used. How-
ever, these observations need to be studied more
consistently to be confirmed. The study reflects all
the disadvantages associated with non-randomised,
retrospective, single-center studies. The small sample
size and the short follow-up period are other
limitations.
In conclusion, femoral-infrapopliteal bypass using
cold-stored saphenous vein allograft is an acceptable
alternative for limb salvage when an autogenous
vein is unavailable and the use of a prosthetic graft
is not recommended. Only a vascular surgery unit
Eur J Vasc Endovasc Surg Vol 34, October 2007closely integrated with a Transplant Center has the
opportunity to use this type of allogenous material.
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